Research findings last week included US vaccines maker Vaxcyte releasing highly impressive Phase III data for its VAX-31, for ...

A U.S. specialty biopharmaceutical company focused on dermatology, with operations centered on commercialization and late-stage development. The company is publicly listed on NYSE American under ...

A San Francisco-based biotech company developing therapies that address age-related diseases. Founded in 2021 by Joe Betts-LaCroix and initially funded with $180 million from OpenAI CEO Sam Altman, ...

A clinical-stage cell therapy company developing autologous and allogeneic switchable CAR-T cell therapies. In October 2024, AvanCell announced that it raised $112 million in Series B financing, which ...

US biopharma company Mineralys Therapeutics today announced the presentation of a new analysis from its pivotal Phase III ...

Given the impact of the illegal medicines trade on public health in Latin America, on confidence in the health system and on ...

US biotech Outlook Therapeutics, which is specializing in the development and commercialization of Lytenava (bevacizumab-vikg ...

Leading Swiss contract development and manufacturing organization (CDMO) Lonza and Onava, a US biotech building an AI-native ...

Israel-based Teva Pharmaceutical Industries US subsidiary today revealed that the US Food and Drug Administration (FDA) has ...

Data presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026 showed that Eli Lilly’s ...

India's pharmaceutical manufacturing industry is entering a delicate phase in its development. As uncertainty grows over its ...

Iambic Therapeutics, the San Diego-based AI drug discovery company, has set terms for a Nasdaq initial public offering of 9,375,000 shares priced at $15 to $17 each, under the proposed ticker IAM, ...